BIB:NSD-ProShares Ultra Nasdaq Biotechnology

ETF | Trading--Leveraged Equity | NASDAQ Global Market

Last Closing

USD 54.62

Change

+0.52 (+0.96)%

Market Cap

USD 0.44B

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index?. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

Inception Date: 06/04/2010

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.04%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
TQQQ ProShares UltraPro QQQ 0.95 %

-2.95 (-5.02%)

USD 22.36B

ETFs Containing BIB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.77% 67% D+ 90% A-
Dividend Return N/A N/A N/A N/A F
Total Return 29.77% 67% D+ 90% A-
Trailing 12 Months  
Capital Gain -10.12% 100% F 51% F
Dividend Return N/A N/A N/A N/A F
Total Return -10.12% 100% F 49% F
Trailing 5 Years  
Capital Gain 21.93% 50% F 56% F
Dividend Return N/A N/A N/A N/A F
Total Return 21.93% 50% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 13.62% 67% D+ 67% D+
Dividend Return 13.62% 67% D+ 64% D
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 46.85% 33% F 22% F
Risk Adjusted Return 29.07% 67% D+ 46% F
Market Capitalization 0.44B 67% D+ 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.